|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000157765 |
Summary for SLC34A2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000157765 | Gene symbol | SLC34A2 |
| Gene name | solute carrier family 34 member 2 | |
| HGNC | 11020 | |
| Entrez ID | 10568 | |
| Gene type | protein_coding | |
| Synonyms | SLC34A2|NAPI-3B | |
| UniProtAcc | O95436 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for SLC34A2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| SLC34A2 | 2.66e+03 | -4.78e+00 | 7.64e-01 | -6.25e+00 | 4.04e-10 | 1.36e-07 | BRCA |
| SLC34A2 | 9.49e+01 | 2.05e+00 | 3.54e-01 | 5.78e+00 | 7.36e-09 | 2.09e-06 | BLCA |
| SLC34A2 | 2.10e+02 | -2.06e+00 | 3.48e-01 | -5.91e+00 | 3.38e-09 | 2.20e-07 | LIHC |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| SLC34A2 | 9.01e+04 | -1.07e+00 | 3.22e-01 | -3.32e+00 | 9.10e-04 | 1.97e-03 | LUAD |
| SLC34A2 | 1.16e+02 | 5.10e+00 | 1.09e+00 | 4.67e+00 | 2.94e-06 | 2.02e-05 | BLCA |
| SLC34A2 | 2.40e+04 | 3.94e+00 | 3.94e-01 | 1.00e+01 | 1.45e-23 | 4.64e-22 | KIRP |
| SLC34A2 | 3.99e+03 | 4.23e+00 | 6.85e-01 | 6.18e+00 | 6.28e-10 | 9.18e-09 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| SLC34A2 | 9.96e+02 | 2.26e+00 | 7.83e-01 | 2.89e+00 | 3.86e-03 | 1.63e-02 | STAD |
Top |
Sex-biased somatic mutation for SLC34A2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for SLC34A2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg19766441 | chr4:25655743 | CGI:chr4:25655497-25655925 | promoter,gene body | 2.20e-01 | 4.25e-01 | -1.97e+00 | 4.83e-02 | 4.93e-02 | -2.05e-01 |
| BRCA | cg21200703 | chr4:25656006 | CGI:chr4:25655497-25655925 | promoter,gene body | 3.92e-01 | 5.63e-01 | -2.11e+00 | 3.52e-02 | 4.37e-02 | -1.71e-01 |
| KIRP | cg09157302 | chr4:25655208 | CGI:chr4:25655497-25655925 | promoter | 2.71e-01 | 1.69e-01 | 3.66e+00 | 2.54e-04 | 1.68e-03 | 1.01e-01 |
| KIRP | cg02272859 | chr4:25654892 | CGI:chr4:25655497-25655925 | promoter | 4.85e-01 | 3.81e-01 | 3.19e+00 | 1.43e-03 | 6.18e-03 | 1.04e-01 |
| KIRP | cg04101194 | chr4:25655243 | CGI:chr4:25655497-25655925 | promoter | 2.96e-01 | 1.91e-01 | 3.27e+00 | 1.09e-03 | 5.12e-03 | 1.05e-01 |
| KIRP | cg04242577 | chr4:25656299 | CGI:chr4:25655497-25655925 | promoter,gene body | 5.19e-01 | 4.03e-01 | 3.48e+00 | 5.09e-04 | 2.91e-03 | 1.16e-01 |
| KIRP | cg25285433 | chr4:25656329 | CGI:chr4:25655497-25655925 | promoter,gene body | 5.82e-01 | 4.44e-01 | 3.56e+00 | 3.78e-04 | 2.31e-03 | 1.39e-01 |
| ESCA | cg07578695 | chr4:25655792 | CGI:chr4:25655497-25655925 | promoter,gene body | 1.95e-01 | 8.03e-02 | 2.22e+00 | 2.65e-02 | 4.21e-02 | 1.15e-01 |
| ESCA | cg19616230 | chr4:25655807 | CGI:chr4:25655497-25655925 | promoter,gene body | 3.08e-01 | 1.81e-01 | 2.58e+00 | 9.90e-03 | 2.65e-02 | 1.27e-01 |
| ESCA | cg27513574 | chr4:25655818 | CGI:chr4:25655497-25655925 | promoter,gene body | 2.00e-01 | 6.88e-02 | 2.22e+00 | 2.65e-02 | 4.21e-02 | 1.32e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| HNSC | cg07578695 | chr4:25655792 | CGI:chr4:25655497-25655925 | promoter,gene body | 1.81e-01 | 4.56e-02 | 3.21e+00 | 1.32e-03 | 2.29e-03 | 1.35e-01 |
| HNSC | cg27513574 | chr4:25655818 | CGI:chr4:25655497-25655925 | promoter,gene body | 1.81e-01 | 2.53e-02 | 3.41e+00 | 6.56e-04 | 1.27e-03 | 1.56e-01 |
| HNSC | cg01493016 | chr4:25655781 | CGI:chr4:25655497-25655925 | promoter,gene body | 2.47e-01 | 1.34e-01 | 3.37e+00 | 7.61e-04 | 1.44e-03 | 1.13e-01 |
| LUSC | cg09157302 | chr4:25655208 | CGI:chr4:25655497-25655925 | promoter | 3.70e-01 | 1.92e-02 | 4.43e+00 | 9.32e-06 | 5.26e-04 | 3.50e-01 |
| LUSC | cg07578695 | chr4:25655792 | CGI:chr4:25655497-25655925 | promoter,gene body | 1.88e-01 | 3.34e-02 | 2.86e+00 | 4.19e-03 | 7.14e-03 | 1.54e-01 |
| LUSC | cg19616230 | chr4:25655807 | CGI:chr4:25655497-25655925 | promoter,gene body | 2.92e-01 | 1.36e-01 | 2.56e+00 | 1.05e-02 | 1.44e-02 | 1.55e-01 |
| LUSC | cg19766441 | chr4:25655743 | CGI:chr4:25655497-25655925 | promoter,gene body | 1.87e-01 | 3.99e-02 | 2.26e+00 | 2.38e-02 | 2.74e-02 | 1.47e-01 |
| LUSC | cg27513574 | chr4:25655818 | CGI:chr4:25655497-25655925 | promoter,gene body | 1.79e-01 | 1.63e-02 | 3.01e+00 | 2.57e-03 | 5.00e-03 | 1.63e-01 |
| LUSC | cg02272859 | chr4:25654892 | CGI:chr4:25655497-25655925 | promoter | 7.21e-01 | 4.97e-01 | 3.88e+00 | 1.04e-04 | 7.08e-04 | 2.24e-01 |
| LUSC | cg04101194 | chr4:25655243 | CGI:chr4:25655497-25655925 | promoter | 4.28e-01 | 5.78e-02 | 4.24e+00 | 2.20e-05 | 5.26e-04 | 3.70e-01 |
| LUSC | cg01493016 | chr4:25655781 | CGI:chr4:25655497-25655925 | promoter,gene body | 2.52e-01 | 1.14e-01 | 2.82e+00 | 4.78e-03 | 7.89e-03 | 1.39e-01 |
| LUSC | cg04242577 | chr4:25656299 | CGI:chr4:25655497-25655925 | promoter,gene body | 6.46e-01 | 4.76e-01 | 3.39e+00 | 6.95e-04 | 2.05e-03 | 1.70e-01 |
| LUSC | cg25285433 | chr4:25656329 | CGI:chr4:25655497-25655925 | promoter,gene body | 7.29e-01 | 5.51e-01 | 3.49e+00 | 4.74e-04 | 1.60e-03 | 1.77e-01 |
| LUSC | cg19299094 | chr4:25656413 | CGI:chr4:25655497-25655925 | promoter,gene body | 3.60e-01 | 2.08e-01 | 3.26e+00 | 1.10e-03 | 2.76e-03 | 1.52e-01 |
| BLCA | cg25285433 | chr4:25656329 | CGI:chr4:25655497-25655925 | promoter,gene body | 6.92e-01 | 8.01e-01 | -2.13e+00 | 3.36e-02 | 3.67e-02 | -1.09e-01 |
| KIRP | cg09157302 | chr4:25655208 | CGI:chr4:25655497-25655925 | promoter | 1.69e-01 | 3.17e-01 | -3.57e+00 | 3.57e-04 | 7.62e-04 | -1.48e-01 |
| KIRP | cg02272859 | chr4:25654892 | CGI:chr4:25655497-25655925 | promoter | 3.81e-01 | 6.12e-01 | -4.60e+00 | 4.28e-06 | 1.83e-05 | -2.31e-01 |
| KIRP | cg04101194 | chr4:25655243 | CGI:chr4:25655497-25655925 | promoter | 1.91e-01 | 3.81e-01 | -3.66e+00 | 2.48e-04 | 5.60e-04 | -1.90e-01 |
| KIRP | cg04242577 | chr4:25656299 | CGI:chr4:25655497-25655925 | promoter,gene body | 4.03e-01 | 5.18e-01 | -3.50e+00 | 4.71e-04 | 9.62e-04 | -1.15e-01 |
| KIRP | cg25285433 | chr4:25656329 | CGI:chr4:25655497-25655925 | promoter,gene body | 4.44e-01 | 6.99e-01 | -3.68e+00 | 2.36e-04 | 5.37e-04 | -2.56e-01 |
| KIRP | cg19299094 | chr4:25656413 | CGI:chr4:25655497-25655925 | promoter,gene body | 2.29e-01 | 3.44e-01 | -3.92e+00 | 8.83e-05 | 2.33e-04 | -1.15e-01 |
| ESCA | cg09157302 | chr4:25655208 | CGI:chr4:25655497-25655925 | promoter | 2.78e-01 | 1.20e-01 | 2.07e+00 | 3.80e-02 | 4.61e-02 | 1.59e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg07578695 | chr4:25655792 | CGI:chr4:25655497-25655925 | promoter,gene body | 1.59e-01 | 3.25e-02 | 8.53e+00 | 1.52e-17 | 6.75e-17 | 1.26e-01 |
| BRCA | cg19616230 | chr4:25655807 | CGI:chr4:25655497-25655925 | promoter,gene body | 2.62e-01 | 1.20e-01 | 7.80e+00 | 6.19e-15 | 2.24e-14 | 1.43e-01 |
| BRCA | cg19766441 | chr4:25655743 | CGI:chr4:25655497-25655925 | promoter,gene body | 2.20e-01 | 2.76e-02 | 9.81e+00 | 1.06e-22 | 7.25e-22 | 1.93e-01 |
| BRCA | cg27513574 | chr4:25655818 | CGI:chr4:25655497-25655925 | promoter,gene body | 1.65e-01 | 2.23e-02 | 8.61e+00 | 7.47e-18 | 3.39e-17 | 1.42e-01 |
| BRCA | cg21200703 | chr4:25656006 | CGI:chr4:25655497-25655925 | promoter,gene body | 3.92e-01 | 2.51e-01 | 7.42e+00 | 1.14e-13 | 3.74e-13 | 1.41e-01 |
| KIRC | cg25285433 | chr4:25656329 | CGI:chr4:25655497-25655925 | promoter,gene body | 7.73e-01 | 6.66e-01 | 2.24e+00 | 2.50e-02 | 3.12e-02 | 1.07e-01 |
| THCA | cg02272859 | chr4:25654892 | CGI:chr4:25655497-25655925 | promoter | 6.00e-01 | 7.13e-01 | -3.50e+00 | 4.61e-04 | 1.15e-03 | -1.13e-01 |
| KIRP | cg19616230 | chr4:25655807 | CGI:chr4:25655497-25655925 | promoter,gene body | 2.36e-01 | 1.02e-01 | 2.14e+00 | 3.26e-02 | 3.72e-02 | 1.35e-01 |
| KIRP | cg19766441 | chr4:25655743 | CGI:chr4:25655497-25655925 | promoter,gene body | 1.23e-01 | 2.02e-02 | 2.60e+00 | 9.43e-03 | 1.62e-02 | 1.03e-01 |
Top |
Exon skipping events with PSI in TCGA for SLC34A2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for SLC34A2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for SLC34A2 |
| TFs related to SLC34A2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| SLC34A2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for SLC34A2 |
| RBPs related to ES in SLC34A2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| LUSC | SAMD4A | exon_skip_422879 | 5.98e+00 | 1.59e-03 | 6.53e+00 | 9.81e-01 | Female-biased |
| SLC34A2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000157765 | FRGCA,hsa-mir-1298,SLC34A2 | Male-specific ceRNA | TCGA-KIRP |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs1800908 | chr4:26490600:C:A | - | 0.154677795541631 | 0.000414632702301811 | LIHC | Female-baised eQTL |
| rs16873777 | chr4:23499051:A:G | - | 0.123393481418919 | 0.0107128889352609 | LIHC | Female-baised eQTL |
| rs16873779 | chr4:23499082:A:G | - | 0.123393481418919 | 0.0107128889352609 | LIHC | Female-baised eQTL |
| rs113836717 | chr4:23501260:G:A | - | 0.123393481418919 | 0.0107128889352609 | LIHC | Female-baised eQTL |
| rs113370805 | chr4:23505060:C:T | - | 0.123393481418919 | 0.0107128889352609 | LIHC | Female-baised eQTL |
| rs78119922 | chr4:23509743:T:C | - | 0.123393481418919 | 0.0107128889352609 | LIHC | Female-baised eQTL |
| rs112641949 | chr4:23510019:A:G | - | 0.123393481418919 | 0.0107128889352609 | LIHC | Female-baised eQTL |
| rs1155194 | chr4:23515012:G:A | - | 0.123381873097557 | 0.0108109710731037 | LIHC | Female-baised eQTL |
| rs16873871 | chr4:23549089:A:G | - | 0.123484503460875 | 0.0110252628591124 | LIHC | Female-baised eQTL |
| rs76979264 | chr4:23524881:G:A | - | 0.123343242073815 | 0.0110453999233831 | LIHC | Female-baised eQTL |
| rs115711597 | chr4:23526138:T:C | - | 0.123343242073815 | 0.0110453999233831 | LIHC | Female-baised eQTL |
| rs993693 | chr4:23533637:G:A | - | 0.123343242073815 | 0.0110453999233831 | LIHC | Female-baised eQTL |
| rs149085926 | chr4:23535709:C:A | - | 0.123343242073815 | 0.0110453999233831 | LIHC | Female-baised eQTL |
| rs77512760 | chr4:23539382:A:T | - | 0.123343242073815 | 0.0110453999233831 | LIHC | Female-baised eQTL |
| rs869473 | chr4:23540855:G:T | - | 0.123343242073815 | 0.0110453999233831 | LIHC | Female-baised eQTL |
| rs59046113 | chr4:23542130:T:C | - | 0.123343242073815 | 0.0110453999233831 | LIHC | Female-baised eQTL |
| rs79726233 | chr4:23543260:G:A | - | 0.123343242073815 | 0.0110453999233831 | LIHC | Female-baised eQTL |
| rs57506072 | chr4:23548165:A:C | - | 0.116079303693398 | 0.0203150165151139 | LIHC | Female-baised eQTL |
| rs7692809 | chr4:21993585:A:T | - | 0.0649643637232595 | 0.0374629150555041 | STAD | Female-baised eQTL |
| rs143796064 | chr4:21999525:A:T | - | 0.0653564426782446 | 0.0377449336640288 | STAD | Female-baised eQTL |
| rs7672660 | chr4:21997536:A:C | - | 0.0647044144725817 | 0.0420301788553606 | STAD | Female-baised eQTL |
| rs7672668 | chr4:21997547:A:C | - | 0.0647044144725817 | 0.0420301788553606 | STAD | Female-baised eQTL |
| rs115124281 | chr4:21998998:T:C | - | 0.0647044144725817 | 0.0420301788553606 | STAD | Female-baised eQTL |
| rs114117756 | chr4:21999037:C:T | - | 0.0647044144725817 | 0.0420301788553606 | STAD | Female-baised eQTL |
| rs144920180 | chr4:22001723:T:C | - | 0.0647044144725817 | 0.0420301788553606 | STAD | Female-baised eQTL |
| rs4697255 | chr4:21988438:G:T | - | 0.0636067766729497 | 0.0469010507248976 | STAD | Female-baised eQTL |
| rs34357633 | chr4:21988040:C:T | - | 0.0633518318789775 | 0.0479870151600514 | STAD | Female-baised eQTL |
| rs4697256 | chr4:21988441:A:G | - | 0.0633518318789775 | 0.0479870151600514 | STAD | Female-baised eQTL |
| rs73106159 | chr4:22672762:G:A | - | 0.0928126823136982 | 0.01680674052005 | KIRC | Female-baised eQTL |
| rs56358079 | chr4:18664702:T:C | - | 0.120837439902295 | 0.0176069477493721 | KIRC | Female-baised eQTL |
| rs80216118 | chr4:18666212:C:T | - | 0.120837439902295 | 0.0176069477493721 | KIRC | Female-baised eQTL |
| rs6841197 | chr4:22664432:G:A | - | 0.0925031041612982 | 0.0178696686164931 | KIRC | Female-baised eQTL |
| rs73106153 | chr4:22665049:T:G | - | 0.0805298090048262 | 0.031282314506165 | KIRC | Female-baised eQTL |
| rs61069572 | chr4:22666658:A:G | - | 0.0805298090048262 | 0.031282314506165 | KIRC | Female-baised eQTL |
| rs6820211 | chr4:22668492:G:C | - | 0.0805298090048262 | 0.031282314506165 | KIRC | Female-baised eQTL |
| rs73106221 | chr4:30361008:A:G | - | 0.102860885370309 | 0.0318557412638303 | KIRC | Female-baised eQTL |
| rs73106224 | chr4:30361994:A:G | - | 0.102860885370309 | 0.0318557412638303 | KIRC | Female-baised eQTL |
| rs57253906 | chr4:30362274:T:C | - | 0.102860885370309 | 0.0318557412638303 | KIRC | Female-baised eQTL |
| rs73106228 | chr4:30364017:C:G | - | 0.102860885370309 | 0.0318557412638303 | KIRC | Female-baised eQTL |
| rs73106230 | chr4:30366473:T:C | - | 0.102860885370309 | 0.0318557412638303 | KIRC | Female-baised eQTL |
| rs4543111 | chr4:18663880:T:C | - | 0.112912572705472 | 0.0328596957221326 | KIRC | Female-baised eQTL |
| rs73106220 | chr4:30360586:T:C | - | 0.109175789215738 | 0.0433443990170683 | KIRC | Female-baised eQTL |
| rs113045612 | chr4:30383343:A:G | - | 0.108848039392053 | 0.0450220219613526 | KIRC | Female-baised eQTL |
| rs58933641 | chr4:30370202:G:A | - | 0.108240517478302 | 0.0481731947081687 | KIRC | Female-baised eQTL |
| rs60327272 | chr4:30370255:G:C | - | 0.108240517478302 | 0.0481731947081687 | KIRC | Female-baised eQTL |
| rs79301102 | chr4:30372986:C:T | - | 0.108240517478302 | 0.0481731947081687 | KIRC | Female-baised eQTL |
| rs79754450 | chr4:30373254:T:C | - | 0.108240517478302 | 0.0481731947081687 | KIRC | Female-baised eQTL |
| rs77929416 | chr4:30371774:C:T | - | 0.108080285720716 | 0.0491815863473149 | KIRC | Female-baised eQTL |
| rs1491364 | chr4:20781054:T:A | - | -0.0470504629241265 | 0.0116713365753573 | LUAD | Female-baised eQTL |
| rs149850953 | chr4:20782040:T:A | - | -0.0470504629241265 | 0.0116713365753573 | LUAD | Female-baised eQTL |
| rs1491363 | chr4:20780977:C:T | - | -0.0451968825184608 | 0.0241543399485696 | LUAD | Female-baised eQTL |
| rs6843196 | chr4:20795083:C:T | - | -0.0445720309466429 | 0.0258524776501955 | LUAD | Female-baised eQTL |
| rs16869962 | chr4:20779463:A:G | - | -0.0448010972913123 | 0.0260572428712414 | LUAD | Female-baised eQTL |
| rs13149493 | chr4:20793275:T:A | - | -0.0445674312890646 | 0.0288844587248234 | LUAD | Female-baised eQTL |
| rs3857162 | chr4:20769439:A:C | - | -0.0464804708069493 | 0.0308784277899451 | LUAD | Female-baised eQTL |
| rs13105793 | chr4:20803757:A:G | - | -0.043752259969789 | 0.0315203665239506 | LUAD | Female-baised eQTL |
| rs13105988 | chr4:20803772:C:A | - | -0.043752259969789 | 0.0315203665239506 | LUAD | Female-baised eQTL |
| rs28493967 | chr4:20803884:C:T | - | -0.043752259969789 | 0.0315203665239506 | LUAD | Female-baised eQTL |
| rs7695244 | chr4:20805491:T:C | - | -0.043752259969789 | 0.0315203665239506 | LUAD | Female-baised eQTL |
| rs13101953 | chr4:20806051:T:C | - | -0.0428451937811703 | 0.0413111575324255 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs77077746 | chr4:27169054:A:G | - | 0.0489699695527385 | 0.0233474110895315 | LIHC | Male-baised eQTL |
| rs75323825 | chr4:27141596:C:A | - | 0.051954927667598 | 0.0344610784216967 | LIHC | Male-baised eQTL |
| rs61795433 | chr4:31263544:T:A | - | 0.091519700480703 | 0.0164668405165565 | LUSC | Male-baised eQTL |
| rs61795432 | chr4:31261286:G:T | - | 0.091495819460212 | 0.0165398919225907 | LUSC | Male-baised eQTL |
| rs11725352 | chr4:31260183:G:A | - | 0.0862954868766581 | 0.0301380830773663 | LUSC | Male-baised eQTL |
| rs61795430 | chr4:31253428:T:G | - | 0.0831843104737378 | 0.0305107500751258 | LUSC | Male-baised eQTL |
| rs1348873 | chr4:22899479:T:C | - | 0.0774955172689678 | 0.000965180051027487 | STAD | Male-baised eQTL |
| rs4361384 | chr4:21122078:T:C | - | 0.0564617793826275 | 0.0275109911355357 | STAD | Male-baised eQTL |
| rs75012865 | chr4:19745229:C:T | - | 0.056755981679213 | 0.0290420930293565 | STAD | Male-baised eQTL |
| rs62295106 | chr4:19747482:A:G | - | 0.0536557220664755 | 0.0308636350279088 | STAD | Male-baised eQTL |
| rs16897955 | chr4:19010980:C:T | - | 0.0577131230159171 | 0.037805372194664 | STAD | Male-baised eQTL |
| rs62295103 | chr4:19746262:T:A | - | 0.0521495840784985 | 0.0395099350488675 | STAD | Male-baised eQTL |
| rs4511994 | chr4:19747198:T:C | - | 0.0521495840784985 | 0.0395099350488675 | STAD | Male-baised eQTL |
| rs62295105 | chr4:19747336:G:C | - | 0.0521495840784985 | 0.0395099350488675 | STAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of SLC34A2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000157765 | SLC34A2 | C0007131 | Non-Small Cell Lung Carcinoma | 2 | CTD_human |
| ENSG00000157765 | SLC34A2 | C0013221 | Drug toxicity | 1 | CTD_human |
| ENSG00000157765 | SLC34A2 | C0041755 | Adverse reaction to drug | 1 | CTD_human |
| ENSG00000157765 | SLC34A2 | C0155912 | Pulmonary Alveolar Microlithiasis | 1 | CTD_human |
